NO965621D0 - Nye hIL-4-mutantproteiner som antagonister eller partielle agonister for det humane interleukin 4 - Google Patents

Nye hIL-4-mutantproteiner som antagonister eller partielle agonister for det humane interleukin 4

Info

Publication number
NO965621D0
NO965621D0 NO965621A NO965621A NO965621D0 NO 965621 D0 NO965621 D0 NO 965621D0 NO 965621 A NO965621 A NO 965621A NO 965621 A NO965621 A NO 965621A NO 965621 D0 NO965621 D0 NO 965621D0
Authority
NO
Norway
Prior art keywords
mutant proteins
pct
antagonists
human interleukin
partial agonists
Prior art date
Application number
NO965621A
Other languages
English (en)
Other versions
NO965621L (no
Inventor
Hanno Wild
Rudolf Hanko
Michael Doerschug
Hans-Dietrich Hoerlein
Juergen Beunink
Heiner Apeler
Hermann Wehlmann
Walter Sebald
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO965621L publication Critical patent/NO965621L/no
Publication of NO965621D0 publication Critical patent/NO965621D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
NO965621A 1994-07-01 1996-12-30 Nye hIL-4-mutantproteiner som antagonister eller partielle agonister for det humane interleukin 4 NO965621D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4423131A DE4423131A1 (de) 1994-07-01 1994-07-01 Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
PCT/EP1995/002358 WO1996001274A1 (de) 1994-07-01 1995-06-19 NEUE hIL-4-MUTANTENPROTEINE ALS ANTAGONISTEN ODER PARTIELLE AGONISTEN DES HUMANEN INTERLEUKIN 4

Publications (2)

Publication Number Publication Date
NO965621L NO965621L (no) 1996-12-30
NO965621D0 true NO965621D0 (no) 1996-12-30

Family

ID=6522032

Family Applications (1)

Application Number Title Priority Date Filing Date
NO965621A NO965621D0 (no) 1994-07-01 1996-12-30 Nye hIL-4-mutantproteiner som antagonister eller partielle agonister for det humane interleukin 4

Country Status (18)

Country Link
US (1) US6130318A (no)
EP (1) EP0769020B1 (no)
JP (3) JPH10502360A (no)
KR (1) KR100393508B1 (no)
AT (1) ATE190068T1 (no)
AU (1) AU705745B2 (no)
CA (1) CA2193993C (no)
CZ (1) CZ292703B6 (no)
DE (2) DE4423131A1 (no)
DK (1) DK0769020T3 (no)
ES (1) ES2145280T3 (no)
GR (1) GR3033498T3 (no)
HU (1) HU221416B1 (no)
NO (1) NO965621D0 (no)
SK (1) SK284391B6 (no)
TW (1) TW458984B (no)
WO (1) WO1996001274A1 (no)
ZA (1) ZA955443B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9415379D0 (en) * 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
WO1999025732A2 (en) 1997-11-13 1999-05-27 Europäisches Laboratorium für Molekularbiologie (EMBL) Design of coiled-coil dimer derived antagonists of 4-helix bundle cytokine specific receptors
EP2158923B1 (en) 1998-08-06 2013-02-27 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
JP5010798B2 (ja) 2001-10-03 2012-08-29 プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 自己免疫疾患を抑制するためのコポリマー、及びその使用方法
WO2004066704A2 (en) * 2003-01-17 2004-08-12 Cornell Research Foundation, Inc. Injectable hydrogel microspheres from aqueous two-phase system
US7785580B2 (en) * 2003-08-29 2010-08-31 Aerovance, Inc. Modified IL-4 mutein receptor antagonists
US7404957B2 (en) * 2003-08-29 2008-07-29 Aerovance, Inc. Modified IL-4 mutein receptor antagonists
US7635754B2 (en) * 2004-09-22 2009-12-22 Aerovance, Inc. Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
WO2006079169A1 (en) * 2005-01-25 2006-08-03 Apollo Life Sciences Limited Parameter selected gm-csf, il-3, il-4, il-5 and chimeras thereof for therapeutic and diagnostic purposes
PL3321359T3 (pl) 2005-04-11 2021-06-28 Horizon Pharma Rheumatology Llc Wariantowe postacie oksydazy moczanowej i ich zastosowanie
RU2435847C2 (ru) * 2005-04-11 2011-12-10 Савиент Фармасьютикалз, Инк. Вариантная форма урат-оксидазы и ее использование
US20070009479A1 (en) * 2005-06-17 2007-01-11 Aerovance, Inc. Methods for treating dermatitis using mutant human IL-4 compositions
CA2635996A1 (en) * 2006-01-11 2007-07-19 Aerovance, Inc. Methods and compositions for treating asthma in human and non human primates
JP2010514409A (ja) * 2006-06-21 2010-05-06 アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツング ヒトの癌における鑑別式サイトカイン発現
CA2656135A1 (en) * 2006-07-06 2008-01-10 Apogenix Gmbh Human il-4 muteins in cancer therapy
WO2008101671A2 (en) * 2007-02-19 2008-08-28 Apogenix Gmbh Il-4 fc fusion proteins
CN101784280A (zh) * 2007-07-11 2010-07-21 艾罗文斯公司 药物多肽干粉气溶胶制剂及制备方法
JP2009217498A (ja) * 2008-03-10 2009-09-24 Sato Knowledge & Intellectual Property Institute 印字試験システム
US8182626B2 (en) 2008-10-30 2012-05-22 Continental Ag Tire composition with improved vulcanizing agent
KR101861547B1 (ko) 2009-06-25 2018-07-02 크레알타 파마슈티칼스 엘엘씨 페길화된 유리카아제 치료 중에 혈청 요산을 모니터링하여 주입 반응의 위험성 및 반응의 항체­매개 상실을 예측하는 방법 및 키트
CN110615835A (zh) * 2012-08-09 2019-12-27 利兰斯坦福初级大学董事会 选择性地操纵靶细胞中对两个或更多个共有受体多肽识别的配体的细胞反应的方法
EP2813242A1 (en) * 2013-06-13 2014-12-17 PLS-Design GmbH Low molecular weight immune-modulators as adjuvants for specific immunotherapy
CA2925417C (en) 2013-09-24 2023-10-24 Fahar Merchant Interleukin-4 receptor-binding fusion proteins and uses thereof
CN112538108B (zh) * 2020-12-24 2022-06-28 郑州大学 高亲和pvr突变体

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) * 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
EP0052322B1 (de) * 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) * 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) * 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) * 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) * 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3336583A1 (de) * 1983-09-26 1985-04-25 Udo Dr. 8400 Regensburg Ehrenfeld Erzeugnis zur diagnose und therapie von malignen tumoren
US4615885A (en) * 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
EP0272253A4 (en) * 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
JPH02501827A (ja) * 1986-12-19 1990-06-21 イミュネックス・コーポレーション ヒト・インターロイキン‐４　ミューテイン
EP0335900A4 (en) * 1986-12-19 1990-12-27 Immunex Corporation Human interleukin-4 muteins
PT88641B (pt) * 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5538884A (en) * 1991-05-02 1996-07-23 Novo Nordisk A/S Rhamnogalacturonase, corresponding DNA sequence, rhamnogalacturonase containing enzyme preparation and use of the enzyme preparation
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life

Also Published As

Publication number Publication date
ES2145280T3 (es) 2000-07-01
ZA955443B (en) 1996-02-13
ATE190068T1 (de) 2000-03-15
WO1996001274A1 (de) 1996-01-18
NO965621L (no) 1996-12-30
CZ292703B6 (cs) 2003-11-12
GR3033498T3 (en) 2000-09-29
TW458984B (en) 2001-10-11
EP0769020A1 (de) 1997-04-23
US6130318A (en) 2000-10-10
DE4423131A1 (de) 1996-01-04
JPH10502360A (ja) 1998-03-03
DK0769020T3 (da) 2000-07-31
KR100393508B1 (ko) 2003-10-23
DE59507920D1 (de) 2000-04-06
CZ384896A3 (en) 1997-06-11
EP0769020B1 (de) 2000-03-01
JP2007051161A (ja) 2007-03-01
SK169296A3 (en) 1997-08-06
HU9603563D0 (en) 1997-02-28
HUT77577A (hu) 1998-06-29
CA2193993A1 (en) 1996-01-18
AU705745B2 (en) 1999-06-03
JP2011102302A (ja) 2011-05-26
AU2885295A (en) 1996-01-25
SK284391B6 (sk) 2005-03-04
HU221416B1 (en) 2002-09-28
CA2193993C (en) 2008-11-18

Similar Documents

Publication Publication Date Title
NO965621L (no) Nye hIL-4-mutantproteiner som antagonister eller partielle agonister for det humane interleukin 4
ATE182623T1 (de) Humanes serum albumin, herstellung und verwendung
ATE179330T1 (de) Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
DK0764209T3 (da) Albuminekspression i gær
NO941681L (no) Humane IL-4 mutant proteiner
DE3688038T2 (de) Verwendung von buspiron zur herstellung von pharmazeutischen zusammensetzungen zur linderung von krankhaften angst.
DK0609280T3 (da) Humane IL-3 varianter
DK0851926T3 (da) Varianter af humant rekombinant gamminterferon (rhu-IFN-gamma) med forøget termisk stabilitet
ATE204021T1 (de) Klonierung, expression und charakterisierung einer neuen form der phosphatidylinositol-3- kinase
ATE275968T1 (de) Mitteln zur behandlung von auto-immun krankheiten
DE69002946D1 (de) Paracetamol enthaltende arzneizubereitung.
DE69315341T2 (de) Antigene regionen von tumorfreigestzten partikeln (tlp) komplexen und antikörper die sie erkennen.
DE69323191T2 (de) Wasserlösliche retinoide
DE58909261D1 (de) Ancrod-proteine, ihre herstellung und verwendung.
ES2098119T3 (es) Nuevas triazoloquinazolinas, su obtencion y empleo.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application